Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

NOP agonist AT-312 can reduce alcohol reward

Feb. 26, 2018

Pain Therapeutics resubmits Remoxy ER NDA

Feb. 14, 2018

Opiant Pharmaceuticals announces plans for intranasal nalmefene

Feb. 13, 2018

V1B receptor antagonism may enhance alcohol dependency treatment

Feb. 6, 2018

Achieve Life Sciences amends technology license agreement with University of Bristol

Jan. 25, 2018

AP-202 shows promise as an agent for nicotine addiction

Jan. 23, 2018

FDA issues complete response letter for CAM-2038 NDA for opioid use disorder

Jan. 22, 2018

Mosedipimod receives FDA orphan drug designation for ARS

Jan. 5, 2018

Addex and Indivior sign licensing and collaboration agreement for ADX-71441 to treat addiction

Jan. 3, 2018

Axsome Therapeutics and Duke University to collaborate on phase II study of AXS-05

Dec. 15, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...